Citius Oncology, Inc. CTOR Long-term material purchase obligations

Long-term material purchase obligations at other companies

CBAK Energy Technology, Inc.CBAT

$10.26M—

MillerKnollMLKN

$17.3M+28.9%

HTF

Heartflow, Inc. Common StockHTFL

$6M+362%

KEE

Keel Infrastructure Corp. Common StockKEEL

$32.42M—

Constellation BrandsSTZ

$1.25B-24.2%

Royal Caribbean GroupRCL

$16.2B+105%

Revenue$1.7M—

Gross profit$1.3M—

Operating income-$28.6M-283%

Net income-$26.6M-244%

EPS (diluted)-$0.27-145%

Cash & equivalents$2.6M+2,350,466%

Total equity$35.3M-1.0%

Total assets$100.7M+10.1%

Operating cash flow-$3.8M-179%

Market cap$60.45M-74.7%

Return on equity-119.9%+46.7pp

Current ratio0.5×+0.1×

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermPurchaseCommitmentAmount.

The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Citius Oncology, Inc.'s long-term material purchase obligations?: Citius Oncology, Inc. (CTOR) reported long-term material purchase obligations of $16.2M in Q4 2025.